Exclusive By Nicholas Florko Trump officials actively lobbied to deny states money for vaccine rollout last fall
Heavyweights By Lev Facher Eric Lander is brilliant, connected, and controversial. Now Joe Biden wants him to ‘reinvigorate’ American science
Politics By Nicholas Florko, Lev Facher, Rachel Cohrs, Andrew Joseph, and Casey Ross The 9 biggest challenges Biden will face on Covid-19, from today on
Politics By Lev Facher and Rachel Cohrs Biden requests $415 billion from Congress to ramp up the country’s Covid-19 response
Politics By Nicholas Florko ‘Everyone is at fault’: With insulin prices skyrocketing, there’s plenty of blame to go around
The Readout LOUD By Damian Garde, Rebecca Robbins, and Adam Feuerstein Listen: A risk for Covid-19 vaccine trials, disappointing data on intermittent fasting, & Trump’s new take on pharma
Health Tech By Alicia Diaz Federal watchdog raises concerns about increasing telehealth fraud during pandemic
The Pharmalot View By Ed Silverman By looking the other way, pharma money helped fuel a toxic political atmosphere in the U.S.
Special Report By Rachel Cohrs Hospitals’ Covid-19 heroics have them poised for power in the new Washington
Politics By Rachel Cohrs After repeated delays, Trump’s HHS punts on oversight of a massive Covid-19 response fund for hospitals
Politics By Lev Facher Major health companies and trade groups suspend campaign contributions after Capitol riot
Politics By Nicholas Florko and Lev Facher Democrats have their best shot yet at letting Medicare negotiate drug prices — but it’s still not a done deal
The Readout LOUD By Damian Garde, Meg Tirrell, and Adam Feuerstein Listen: Biden’s plans for biopharma, a CES preview, & the next phase of the pandemic
First Opinion By Stephen Northrup Looking back and looking ahead: Vioxx, drug safety, and the legacy of Sen. Michael Enzi
Pharmalot By Ed Silverman Sackler family members deny responsibility for the opioid crisis in a rare public appearance
First Opinion By Will Raderman, Elizabeth Pancotti, and Julia Raifman Covid-19 is temporary. The health ramifications of failing to provide adequate economic relief may last decades
Pharmalot By Ed Silverman Sackler family members agree to testify at House hearing on Purdue’s role in opioid crisis
Politics By Nicholas Florko Biden’s HHS pick, Becerra, has taken in more campaign cash from health groups than any other industry
Politics By Nicholas Florko Burr, in line to lead Senate Republicans’ health strategy, has a long history of antagonizing the FDA
Pharmalot By Ed Silverman House passes a bill to close a loophole in a law that gives drug makers ‘unfair’ monopolies
Politics By Andrew Joseph, Lev Facher, Kate Sheridan, and Nicholas Florko Shalala loses — and other 2020 election results that will have big implications for health and science
Politics By Lev Facher, Nicholas Florko, Andrew Joseph, and Kate Sheridan Doctors in Congress, new e-cigarette taxes, stem cells, and abortion rights: Here’s what STAT is watching tonight
Politics By Lev Facher In a pivotal race in North Carolina, Democrats try to paint the incumbent as ‘pharma’s favorite senator’
Pharmalot By Ed Silverman Lawmakers release trove of Purdue documents detailing Sackler family’s involvement in opioid sales